Coya Therapeutics, Inc.
Coya Therapeutics is a clinical-stage biotechnology company developing therapies intended to enhance regulatory T-cell function for neurodegenerative, autoimmune and metabolic diseases. Its potential treatment approaches include Treg-enhancing biologics, Treg-derived exosomes and autologous Treg cell therapy. Its lead candidate, COYA 302, combines low-dose interleukin-2, known as COYA 301, with CTLA4-Ig and is being studied for amyotrophic lateral sclerosis; Coya is also developing it for frontotemporal dementia. COYA 303 combines COYA 301 with a GLP-1 receptor agonist and is an investigational candidate for inflammatory diseases. COYA 301 is also being developed as a standalone biologic. Coya is conducting research and clinical development and has not described commercial product sales. It is headquartered in Houston, Texas.
No SEC Form 4 filings for $COYA in the last 30 days.
See all $COYA insider activity →Coya Therapeutics reported 3Q 2026 revenue of $234.13K, down 93.4% YoY, and a net loss of $10.62M, up 401.8% YoY. The decline was due to lower collaboration revenue and higher R&D spending. The company completed enrollment for its COYA 302 ALS Phase 2/3 trial and received FDA Fast Track Designation. Coya expects its cash to last into 2H 2027.
Coya Therapeutics reported a Q3 2026 net loss of $10.6M, up from $2.1M a year earlier, due to increased R&D costs. Collaboration revenue was $234K, down from $3.6M. The company has $35.8M in cash and expects funding to last into 2H 2027. Enrollment in the Phase 2/3 ALSTARS trial is complete, with topline results expected in early Q2 2027.
Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning COYA (Coya Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 3 bearish.
Recent COYA coverage spans financial news, earnings and corporate actions.
The disappointing earnings and increased loss suggest downside pressure.
The earnings miss and cash burn may weigh on the stock, while trial enrollment completion could be a long‑term catalyst.
The earnings release shows a larger net loss and higher R&D spend, but confirms cash runway and trial enrollment, which may support the stock in the short term while investors await Q2 2027 topline data.
The enrollment completion is a positive milestone but the disclosed loss may weigh on the stock short term.
The extension postpones potential revenue but provides longer efficacy data, likely keeping the stock under pressure until results.
AlphAI scores every news story that mentions COYA with an AI model for sentiment and relevance, and aggregates insider trades from Coya Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Coya Therapeutics reported 3Q 2026 revenue of $234.13K, down 93.4% YoY, and a net loss of $10.62M, up 401.8% YoY. The decline was due to lower collaboration revenue and higher R&D spending. The company completed enrollment for its COYA 302 ALS Phase 2/3 trial and received FDA Fast Track Designation. Coya expects its cash to last into 2H 2027.
Coya Therapeutics reported a Q3 2026 net loss of $10.6M, up from $2.1M a year earlier, due to increased R&D costs. Collaboration revenue was $234K, down from $3.6M. The company has $35.8M in cash and expects funding to last into 2H 2027. Enrollment in the Phase 2/3 ALSTARS trial is complete, with topline results expected in early Q2 2027.
Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance
Coya Therapeutics completed enrollment for its 137-patient ALS trial, ALSTARS, with topline data expected in early Q2 2027. The company reported a Q3 net loss of $10.6M and $35.8M in cash as of September 30, 2026, expected to fund operations into H2 2027. According to Coya, the next major catalyst is the trial readout.
Coya plans to start an open-label extension of its Phase 2/3 ALSTARS trial for COYA 302 in November 2026, delaying its FTD trial to 2027. The company expects its cash runway to extend into the second half of 2027, according to its SEC filing.
Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 14, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing plans to initiate an open-label extension (“OLE”) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotrophic lateral scler
Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 5, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Compa
Coya Therapeutics (COYA) completed enrollment of 120 patients in its Phase 2/3 ALS trial for COYA 302. The company expects topline data in early Q2 2027. This milestone marks progress toward the first controlled efficacy readout for the treatment.
Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 15, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing that the one hundredth (100 th ) patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Company’s co
Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update HOUSTON, TX., August 11, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended t
